Compare iShares Bitcoin Trust (IBIT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs BIO-TECHNE Corp — how do they compare? iShares Bitcoin Trust trades at $46.77 (market cap $68.92B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: iShares Bitcoin Trust is far larger — about 6.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and BIO-TECHNE Corp for 63 Days on average.
| IBIT | TECH | |
|---|---|---|
Market Cap | $68.92B | $11.37B |
Volume | 46,059,179 | 3,153,511 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $72.61 |
52-Week Low | $33.29 | $43.31 |
Typical Hold Time | 40 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.21, down 2.64% on the day, with technical indicators showing a bullish overall signal driven by moving averages. The stock faces immediate support at $46 and resistance at $48. Recent news highlights strong institutional interest with BlackRock's IBIT recording $196 million in daily inflows on October 1, 2026, signaling renewed investor confidence in Bitcoin-focused investment products.
The outlook remains cautiously optimistic given institutional inflows and technical strength, though the absence of traditional financial metrics like P/E and P/S limits fundamental analysis. Key risks include market volatility and regulatory uncertainty, while analyst sentiment appears mixed with technical indicators favoring bullish momentum near-term.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
